Results of our study support early 1-month insulin and metformin treatment’s superiority over glimepiride and metformin in newly diagnosed T2D, on beta cell (BC) functional recovery, glycemic and lipid control, enduring beyond the short span of treatment itself. The gene discussed is INS; the disease is type 2 diabetes mellitus.